EQRx IPO

EQRx was a clinical-stage biotechnology company that aimed to develop and deliver innovative medicines at radically lower prices through a novel business model focused on value-based pricing and global market access. The company's approach involved developing high-quality generic versions of expensive biologics and novel therapeutics while committing to price them significantly below market rates in exchange for volume-based contracts with payers. EQRx raised substantial funding and developed a pipeline of oncology and immunology treatments, but struggled with execution challenges and market dynamics that made their disruptive pricing model difficult to implement effectively. The company was ultimately acquired by Revolution Medicines in 2023, with its assets and pipeline being integrated into the acquiring company's operations.